{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:34:05Z","timestamp":1791952445372,"version":"4.3.4"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000774","name":"DOD | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["OTA 18-06-16 \/ TRE18-16-005"],"award-info":[{"award-number":["OTA 18-06-16 \/ TRE18-16-005"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201800015C"],"award-info":[{"award-number":["HHSO100201800015C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,4,19]]},"abstract":"<jats:p>\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Yersinia pestis<\/jats:named-content>\n            , the causative pathogens for anthrax and plague, respectively, along with\n            <jats:named-content content-type=\"genus-species\">Burkholderia mallei<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Burkholderia pseudomallei<\/jats:named-content>\n            are potential bioterrorism threats. Tebipenem pivoxil hydrobromide (TBP HBr) (formerly SPR994) is an orally available prodrug of tebipenem, a carbapenem with activity versus multidrug-resistant (MDR) Gram-negative pathogens, including quinolone-resistant and extended-spectrum-\u03b2-lactamase-producing\n            <jats:italic>Enterobacterales<\/jats:italic>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.02385-20","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T15:00:45Z","timestamp":1613574045000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat Pathogens"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-8454","authenticated-orcid":true,"given":"Nicholas P.","family":"Clayton","sequence":"first","affiliation":[{"name":"Spero Therapeutics Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Jain","sequence":"additional","affiliation":[{"name":"Spero Therapeutics Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Halasohoris","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Pysz","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Lembirik","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Zumbrun","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Kane","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hackett","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Pfefferle","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Autumn","family":"Smiley","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Heine","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, Department of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel T.","family":"Meister","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pucci","sequence":"additional","affiliation":[{"name":"Spero Therapeutics Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-28994-1_15"},{"key":"e_1_3_2_3_2","first-page":"269","article-title":"Lessons to be learned from recent biosafety incidents in the United States","volume":"17","author":"Weiss S","year":"2015","unstructured":"Weiss S, Yitzhaki S, Shapira SC. 2015. Lessons to be learned from recent biosafety incidents in the United States. Isr Med Assoc J 17:269\u2013273.","journal-title":"Isr Med Assoc J"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0802.010164"},{"key":"e_1_3_2_5_2","volume-title":"Bioterrorism agents\/diseases.","author":"Centers for Disease Control and Prevention","year":"2018","unstructured":"Centers for Disease Control and Prevention. 2018. Bioterrorism agents\/diseases. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/emergency.cdc.gov\/agent\/agentlist-category.asp."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1409755"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2015.0033"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2807\/esm.10.03.00528-en"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.116"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-015-0042-2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2281"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1735"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00181-15"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496821"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp100130b"},{"key":"e_1_3_2_16_2","unstructured":"Citron DM Tyrrell KL Rubio A Goldstein EJC. 2018. In vitro activity of tebipenem (SPR859) tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria abstr SUN-559. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-18"},{"key":"e_1_3_2_18_2","unstructured":"Mendes RE Rhomberg PR Huynh H Cotroneo N Rubio A Flamm RK. 2018. Antimicrobial activity of tebipenem (SPR859) against a global challenge set abstr SUN-558. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_19_2","unstructured":"Mendes RE Rhomberg PR Watters A Cotroneo N Rubio A Flamm RK. 2018. Antimicrobial activity assessment of tebipenem (SPR859) against an isolate collection causing urinary tract infections abstr SUN-560. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_20_2","unstructured":"Zou Y Cotroneo N Rubio A. 2018. In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM) abstr SUN-561. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_21_2","unstructured":"Heang K Grosser L Farrington K Controneo N Jain A Cacarro L Corbett D Rubio A. 2018. In vivo characterization of tebipenem-pivoxil (SPR994) in a murine ascending Escherichia coli urinary tract infection model abstr SUN-565. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_22_2","unstructured":"Grosser L Heang K Teague J Jain A Warn P Corbett D Rubio A. 2018. In vivo efficacy of tebipenem-pivoxil (SPR994) in an acute murine thigh infection caused by Escherichia coli and Klebsiella pneumoniae abstr SUN-566. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_23_2","unstructured":"Teague J Corbet D Burgess E Williams J Evenden P Daws G Vaccaro L Jain A Warn P Rubio A. 2018. In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of Gram-negative bacterial infection abstr SUN-567. Abstr ASM Microbe 2018."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2119-2121.2001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04548-14"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00788-17"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.06.016"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00603-19"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00360-08"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i1.20"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00009"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020353"},{"key":"e_1_3_2_34_2","first-page":"1002","article-title":"Anthrax as a biothreat and our current understanding of this disease","volume":"1","author":"K\u00f6nig R","year":"2013","unstructured":"K\u00f6nig R. 2013. Anthrax as a biothreat and our current understanding of this disease. J Immunol Clin Res 1:1002.","journal-title":"J Immunol Clin Res"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201102-0209CI"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh258"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00464-2"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2006.26.1.3"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49700-1"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.4172\/2157-2526.1000107"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01374-10"},{"key":"e_1_3_2_43_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing, 28th ed. CLSI document M100-ED28. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"28"},{"key":"e_1_3_2_44_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_45_2","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement.","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00292-12"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00288-12"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1947.150.1.70"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1233"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02385-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02385-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:56:15Z","timestamp":1645480575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02385-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4,19]]}},"alternative-id":["10.1128\/AAC.02385-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.02385-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"2020-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02385-20"}}